Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational trial of VB10.16 in advanced cervical cancer patients who failed first line treatment including checkpoint inhibitor treatment

Next Previous
Trial Profile

A registrational trial of VB10.16 in advanced cervical cancer patients who failed first line treatment including checkpoint inhibitor treatment

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VB10 16 (Primary)
  • Indications Cervical cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Nykode Therapeutics

Most Recent Events

  • 05 Sep 2023 According to a Nykode Therapeutics media release, company is looking forward to presenting the trial design and the overall VB10.16 development strategy at our Capital Markets Day in New York on Sep 20, 2023.
  • 05 Sep 2023 According to a Nykode Therapeutics media release, company recently announced FDA approval of its investigational new drug (IND) application for this Phase 2 clinical trial.
  • 22 Dec 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top